The Healthcare Navigator is a platform that helps users to learn about not just treatment options, but also the financial bearings thereof. Photo via thehealthcarenav.com

Taking control of your health can be a difficult path to walk on your own. A new startup, created by eight female Rice University students, is aimed at wading through the health care system.

The Healthcare Navigator is a platform that helps users to learn about not just treatment options, but also the financial bearings thereof.

“About 88 percent of Americans aren’t health literate,” founder and president Kayla Grimes says in a news release. “It’s very hard for them to navigate health care in the way to get the best benefit for it, so what our platform will do is essentially give them the tools and resources to confidently navigate the health care system. We also help with price transparency specifically.”

The multidisciplinary team includes women majoring in pre-med, computer science, medical humanities, art and business. According to Grimes (a rising senior business major), the seed for the idea’s success was planted two years ago when she was volunteering for the National Patient Advocacy Foundation.

“They told me, ‘If you do this right, this could actually change everything in health care,’” she remembers.

Now she and her team have an app, as well as an accessible website, composed of several features all meant to make it easier to save money — and users’ health. The features are:

  • Cost Compass, which compares procedure costs across local hospitals, enabling users to shop around and save money.
  • Care Genius AI, an AI chatbot that helps users to negotiate medical bills and answers health care system questions.
  • Patient Power Modules, which are interactive educational videos that make understanding the health care system easy and engaging.
  • Pocket Doc, which helps consumers find the best providers for them based on location, ratings and quality metrics.
  • Pulse Check Alert keeps users informed on important health care news and patient insights.
  • Care Manager streamlines users’ health care needs and goals in one convenient place.

Grimes says that she hopes that users will skip Google reviews and go straight to their Pocket Doc, which includes information on hospitals, clinics, urgent care centers and freestanding emergency rooms.

“We have that in the system, so that you can actually see useful metrics instead of just going on Google reviews and reading their readmission rate — we’re going to explain what’s a good readmission rate and what’s a bad readmission rate,” she says. “That’s the whole point: We’re not just going to give you these metrics, we’re also going to give you some benchmarks, so you can make the decision for yourself.”

When dealing with your health, knowledge is certainly power, and Healthcare Navigator is bestowing a new kind of power on its users.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.